abaxis inc (ABAX:NASDAQ GS)
abaxis inc (ABAX) Snapshot
|
Open
$46.74
|
Previous Close
$46.89
|
|
|
Day High
$46.96
|
Day Low
$45.59
|
|
|
52 Week High
04/9/13 - $49.45
|
52 Week Low
10/24/12 - $32.41
|
|
|
Market Cap
1.0B
|
Average Volume 10 Days
89.0K
|
|
|
EPS TTM
$0.75
|
Shares Outstanding
22.3M
|
|
|
EX-Date
12/13/12
|
P/E TM
61.2x
|
|
|
Dividend
--
|
Dividend Yield
2.18%
|
Related News
abaxis inc (ABAX) Related Businessweek News
No Related Businessweek News Foundabaxis inc (ABAX) Details
Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient-care setting to provide blood constituent measurements for clinicians worldwide. The company offers point-of-care blood chemistry analyzer, which consists of a compact portable analyzer and a series of single-use plastic discs, called reagent discs, containing all the chemicals required to perform a panel of up to 14 tests on human patients and 13 tests on veterinary patients. It markets the blood analysis systems under the Piccolo Xpress, Piccolo Classic, VetScan VS2, and VetScan Classic names. The company also provides VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, it offers VetScan VSpro, which assists in the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, evaluation of disseminated intravascular coagulation, hepatic disease, monitoring therapy, and the progression of disease states; VetScan VSpro fibrinogen test to provide in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; and i-STAT 1 that delivers blood gas, electrolyte, basic blood chemistry, and hematology results. Further, the company provides Canine Heartworm rapid test to detect dirofilaria immitis in canine whole blood, serum, or plasma; Canine Parvovirus rapid test to detect canine parvovirus antigen in feces; VetScan Giardia rapid test to detect giardiasis, a gastrointestinal infection caused by the protozoan parasite Giardia; and Canine Lyme rapid test to detect Borrelia burgdorferi in canine whole blood, serum, or plasma. Additionally, it offers veterinary reference laboratory diagnostic and consulting services. The company sells its products through direct sales force and independent distributors. Abaxis, Inc. was founded in 1989 and is headquartered in Union City, California.
abaxis inc (ABAX) Top Compensated Officers
abaxis inc (ABAX) Key Developments
Abaxis, Inc. Presents at Jefferies 2013 Global Healthcare Conference, Jun-06-2013 01:30 PM. Venue: Grand Hyatt Hotel, 109 East 42nd Street at Grand Central, New York, New York, United States. Speakers: Clinton H. Severson, Chairman, Chief Executive Officer and President.
Abaxis, Inc. Presents at Stifel Annual Dental & Veterinary Conference, May-29-2013 11:30 AM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Martin V. Mulroy, Chief Commercial Officer for North America Animal Health.
Abaxis, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended March 31, 2013. For the quarter, the company reported revenues of $49,951,000 compared with $42,718,000 for the same period a year ago. Income from operations was $8,986,000 compared with $6,439,000 for the same period a year ago. Income before income tax provision was $8,921,000 compared with $6,890,000 for the same period a year ago. Net income was $6,698,000 or $0.30 per diluted share compared with $4,706,000 or $0.21 per diluted share for the same period a year ago. For the full year, the company reported revenues of $186,025,000 compared with $156,596,000 for the same period a year ago. Income from operations was $42,136,000 compared with $19,457,000 for the same period a year ago. Income before income tax provision was $42,389,000 compared with $20,167,000 for the same period a year ago. Net income was $27,459,000 or $1.23 per diluted share compared with $13,091,000 or $0.58 per diluted share for the same period a year ago.
| Recently Viewed | |||
| ABAX:US | $45.89 USD | -1.00 |  |
| Company | Last | Change |
| ABIOMED Inc | $22.07 USD | +0.07 |
| Cyberonics Inc | $51.02 USD | -0.55 |
| Endologix Inc | $13.28 USD | -0.29 |
| ICU Medical Inc | $73.84 USD | -0.33 |
| NxStage Medical Inc | $14.28 USD | -0.22 |
| View Industry Companies | ||
Industry Analysis
ABAX
Industry Average
| Valuation | ABAX | Industry Range |
| Price/Earnings | 38.2x |
|
| Price/Sales | 5.6x |
|
| Price/Book | 5.9x |
|
| Price/Cash Flow | 38.1x |
|
| TEV/Sales | 5.2x |
|
Post a JobJobs
- Chicago, IL | DunnhumbyusaPosted: Jun 18
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
Sponsored Financial Commentaries
Sponsored Links
To contact ABAXIS INC, please visit www.abaxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
